Compare · MGNX vs XNCR
MGNX vs XNCR
Side-by-side comparison of MacroGenics Inc. (MGNX) and Xencor Inc. (XNCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGNX and XNCR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- XNCR is the larger of the two at $1.11B, about 4.1x MGNX ($272.7M).
- Over the past year, MGNX is up 188.3% and XNCR is up 77.0% - MGNX leads by 111.2 points.
- XNCR has been more active in the news (10 items in the past 4 weeks vs 4 for MGNX).
- MGNX has more recent analyst coverage (25 ratings vs 22 for XNCR).
- Company
- MacroGenics Inc.
- Xencor Inc.
- Price
- $4.29-4.98%
- $14.96-0.07%
- Market cap
- $272.7M
- $1.11B
- 1M return
- +7.64%
- +23.84%
- 1Y return
- +188.26%
- +77.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2013
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 22
MacroGenics Inc.
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Xencor Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., Janssen Biotech, Inc.; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Latest MGNX
- MacroGenics Inc. filed SEC Form 8-K: Leadership Update
- MacroGenics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
- MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
- Director O'Brien Federica F. converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Jackson Scott Thomas converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Heiden William K converted options into 3,750 shares, increasing direct ownership by 3% to 114,750 units (SEC Form 4)
- Director Siegel Jay Philip converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Liu Margaret converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Chhabra Meenu converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
Latest XNCR
- Director Feigal Ellen was granted 10,302 shares, increasing direct ownership by 83% to 22,642 units (SEC Form 4)
- Director Gorman Kevin Charles was granted 10,302 shares, increasing direct ownership by 91% to 21,680 units (SEC Form 4)
- Director Gustafson Kurt A was granted 10,302 shares, increasing direct ownership by 70% to 25,011 units (SEC Form 4)
- Director Klencke Barbara was granted 10,302 shares, increasing direct ownership by 52% to 29,974 units (SEC Form 4)
- Director Montgomery Alan Bruce was granted 10,302 shares, increasing direct ownership by 66% to 25,849 units (SEC Form 4)
- Director Ranieri Richard J was granted 10,302 shares, increasing direct ownership by 75% to 24,011 units (SEC Form 4)
- Director Simpson Todd E was granted 10,302 shares, increasing direct ownership by 75% to 23,988 units (SEC Form 4)
- Director Deshaies Raymond Joseph was granted 10,302 shares (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- Director Feigal Ellen sold $89,370 worth of shares (6,843 units at $13.06) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 12,340 units (SEC Form 4)